Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
182
Views
21
Downloads
Abstract
COVID 19 has emerged as one of the worst pandemics that have distressed the global. Being highly infectious in mild and moderate cases it is likely to cause fever, headache, myalgia, throat irritation and dry cough whereas delayed or insufficient immune reaction leads to a pulmonary phase which manifests as viral pneumonia with hypoxia and in worsens condition typically labelled as ‘cytokine storm’ with excess level of pro‐inflammatory cytokine protein. In order to investigate the efficacy of N‐Acetyl cysteine as a potent nutraceutical in early reversal of RTPCR test in mild and moderate patients of COVID‐19, the present clinical trial was conducted. Patients were divided into two groups’ placebo control and NAC treated and received the experimental drug along with the conventional treatment of COVID (as per Govt. guidelines). Nasopharyngeal samples were collected and analysed for reversal of RTPCR test on day 5th and 7th. Additional number of patients with Negative RTPCR test on day 5th and 7th in NAC treated group is observed as marker of early recovery due to NAC administration in COVID‐19 patients. Therefore we requisite intense research inputs with larger sample size to elucidate the role of NAC in critical and non‐critical COVID‐19 patients.
How to cite this article:
N. Jaiswal, K. J. Patel, S. Saxena, P. Nyati, S. Maurya and H. Shah. Efficacy of N‐Acetyl Cysteine in COVID‐19 Patients: A Randomised Double Blind Placebo Control Clinical Trial in Central India.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.620.625
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.620.625